Literature DB >> 33762410

Defining stable reference genes in HIV latency reversal experiments.

Cristina Ceriani1,2, Gabrielle S Streeter3, Kena J Lemu1, Katherine S James1,2, Simon Ghofrani1,2, Brigitte Allard1,2, Bonnie E Shook-Sa3, David M Margolis1,2,4, Nancie M Archin5,2.   

Abstract

Quantification of cell associated HIV RNA (ca-RNA) is one of the most important and commonly used methods to evaluate the performance of latency-reversing agents (LRAs). Copies of HIV RNA measured by qPCR, are often normalized to the input RNA or cell number. However, these could be affected by biological variability and/or technical errors, which can be avoided by using an internal reference gene. To obtain reliable data, it is essential to select stable reference genes (RGs) of which the expression is not influenced by biological variability, the type of cells, or the LRAs used. However, to date, no study has carefully evaluated RG stability following LRA exposure. We analyzed the stability of six widely used RGs (GAPDH, TBP, YWHAZ, UBE2D2, HPRT1 and RPL27A) in human PBMC and CD4+ T cells. LRA exposure significantly influenced the stability of these RGs. Overall, TBP, UBE2D2, and RPL27A were the most stable RGs in all tested conditions. TBP was generally the most stable RG whereas GAPDH varied the most. Finally, we evaluated the impact of applying different RG normalizers to host genes and HIV ca-RNA data. Altered results were observed both in host and HIV gene expression when unstable RGs were used. Our data underline the importance of testing the stability of RGs utilized to evaluate LRA-induced HIV ca-RNA expression. To our knowledge, this is the first careful evaluation of the stability of RGs after LRA exposure and will significantly contribute to the quality of data analysis in regard to gene expression.IMPORTANCELatency-reversing agents (LRAs) are ubiquitously used in the "shock-and-kill" HIV cure strategy and their performance is often evaluated by ex-vivo quantification of cell associated HIV RNA. HIV RNA, measured by qPCR, is often normalized to internal reference genes, but the expression of these genes should not be influenced by the experimental settings. We found that treatment of human PBMC and CD4+ T cells with LRAs significantly altered the expression of several commonly used reference genes, such as GAPDH. Finally, we evaluate the impact of different reference genes on normalization of host genes and HIV cell associated RNA expression and demonstrated that using unstable reference genes dramatically altered experimental outcome. Our data highlight the importance of using reference genes that are unaffected by LRAs under study to correctly evaluate host gene and cell associated HIV RNA expression induced by latency-reversing agents.
Copyright © 2021 American Society for Microbiology.

Entities:  

Year:  2021        PMID: 33762410      PMCID: PMC8139712          DOI: 10.1128/JVI.02305-20

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 2.  HIV "shock and kill" therapy: In need of revision.

Authors:  Erik Abner; Albert Jordan
Journal:  Antiviral Res       Date:  2019-03-23       Impact factor: 5.970

3.  Development of a universal internal positive control.

Authors:  Mark F Kavlick
Journal:  Biotechniques       Date:  2018-11       Impact factor: 1.993

4.  Identification of Suitable Reference Genes for Peripheral Blood Mononuclear Cell Subset Studies in Multiple Sclerosis.

Authors:  D B Oturai; H B Søndergaard; L Börnsen; F Sellebjerg; J Romme Christensen
Journal:  Scand J Immunol       Date:  2016-01       Impact factor: 3.487

5.  A limited group of class I histone deacetylases acts to repress human immunodeficiency virus type 1 expression.

Authors:  Kara S Keedy; Nancie M Archin; Adam T Gates; Amy Espeseth; Daria J Hazuda; David M Margolis
Journal:  J Virol       Date:  2009-03-11       Impact factor: 5.103

Review 6.  Revisiting global gene expression analysis.

Authors:  Jakob Lovén; David A Orlando; Alla A Sigova; Charles Y Lin; Peter B Rahl; Christopher B Burge; David L Levens; Tong Ihn Lee; Richard A Young
Journal:  Cell       Date:  2012-10-26       Impact factor: 41.582

7.  Evaluation of external RNA controls for the standardisation of gene expression biomarker measurements.

Authors:  Alison S Devonshire; Ramnath Elaswarapu; Carole A Foy
Journal:  BMC Genomics       Date:  2010-11-24       Impact factor: 3.969

8.  Impact of a decade of successful antiretroviral therapy initiated at HIV-1 seroconversion on blood and rectal reservoirs.

Authors:  Eva Malatinkova; Ward De Spiegelaere; Pawel Bonczkowski; Maja Kiselinova; Karen Vervisch; Wim Trypsteen; Margaret Johnson; Chris Verhofstede; Danny de Looze; Charles Murray; Sabine Kinloch-de Loes; Linos Vandekerckhove
Journal:  Elife       Date:  2015-10-06       Impact factor: 8.140

9.  Early treated HIV-1 positive individuals demonstrate similar restriction factor expression profile as long-term non-progressors.

Authors:  Clarissa Van Hecke; Wim Trypsteen; Eva Malatinkova; Ward De Spiegelaere; Karen Vervisch; Sofie Rutsaert; Sabine Kinloch-de Loes; Magdalena Sips; Linos Vandekerckhove
Journal:  EBioMedicine       Date:  2019-02-12       Impact factor: 8.143

Review 10.  Careful selection of reference genes is required for reliable performance of RT-qPCR in human normal and cancer cell lines.

Authors:  Francis Jacob; Rea Guertler; Stephanie Naim; Sheri Nixdorf; André Fedier; Neville F Hacker; Viola Heinzelmann-Schwarz
Journal:  PLoS One       Date:  2013-03-15       Impact factor: 3.240

View more
  2 in total

1.  Stable Latent HIV Infection and Low-level Viremia Despite Treatment With the Broadly Neutralizing Antibody VRC07-523LS and the Latency Reversal Agent Vorinostat.

Authors:  Cynthia L Gay; Katherine S James; Marina Tuyishime; Shane D Falcinelli; Sarah B Joseph; Matthew J Moeser; Brigitte Allard; Jennifer L Kirchherr; Matthew Clohosey; Samuel L M Raines; David C Montefiori; Xiaoying Shen; Robert J Gorelick; Lucio Gama; Adrian B McDermott; Richard A Koup; John R Mascola; Michelle Floris-Moore; JoAnn D Kuruc; Guido Ferrari; Joseph J Eron; Nancie M Archin; David M Margolis
Journal:  J Infect Dis       Date:  2022-03-02       Impact factor: 7.759

2.  Combined noncanonical NF-κB agonism and targeted BET bromodomain inhibition reverse HIV latency ex vivo.

Authors:  Shane D Falcinelli; Jackson J Peterson; Anne-Marie W Turner; David Irlbeck; Jenna Read; Samuel Lm Raines; Katherine S James; Cameron Sutton; Anthony Sanchez; Ann Emery; Gavin Sampey; Robert Ferris; Brigitte Allard; Simon Ghofrani; Jennifer L Kirchherr; Caroline Baker; JoAnn D Kuruc; Cynthia L Gay; Lindsey I James; Guoxin Wu; Paul Zuck; Inmaculada Rioja; Rebecca C Furze; Rab K Prinjha; Bonnie J Howell; Ronald Swanstrom; Edward P Browne; Brian D Strahl; Richard M Dunham; Nancie M Archin; David M Margolis
Journal:  J Clin Invest       Date:  2022-04-15       Impact factor: 19.456

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.